Anti-infectious carbohydrates

• US 7,858,595 B2
• Filed: 09/25/2002
• Issued: 12/28/2010
• Est. Priority Date: 09/25/2001
• Status: Expired due to Fees

• Current Assignee: nv nutricia
• Original Assignee: nv nutricia
• Inventors: Finke, Berndt, Goebel, Werner, Slaghuis, Jorg, Schmitt, Joachim, Stahl, Bernd
• Primary Examiner(s): Jiang; Shaojia Anna
• Assistant Examiner(s): WHITE, EVERETT NMN
• Application Number:
  US10/490,102
• Publication Number:
  US 20050004070A1
• Time in Patent Office: 3,016 Days
• Field of Search: 536/55.2, 536/123.1, 514/54, 514/62, 426/658
• US Class Current: 514/54
• CPC Class Codes: A61K 31/702 Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• CPC Class Codes: A61K 31/715 Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Abstract

Neutral straight-chain or branched oligosaccharides for preventing the invasion and infection of mammal cells by pathogens and for fighting diseases caused by such pathogens are disclosed. Food, dietetic products and pharmaceutical agents containing oligosaccharides consist of a base unit of formula (I), and between 0 and 19 other units of formula (II), which are linked directly or indirectly to the base unit. Gal represents a galactose monosaccharide unit; Glc represents a glucose monosaccharide unit; HexNAc rpresents an N-acetylated galactosamine or glucosamine monosaccharide unit (GalNAc or GlcNAc); R independently represent a β 1-3 or β 1-6 glycosidic link to HexNAc monosaccharide of the next [Gal-HexNAc] unit (II), and on a terminal [Gal-HexNAc] unit, or R are not present; and a terminal [Gal-HexNAc] unit, wherein R represent a deoxyhexose radical, can have another deoxyhexose radical on the HexNAc monosaccharide unit.

Claims

1. A method for treating an infection caused by Listeria bacteria in a patient, comprising:

administering to said patient in need thereof a composition comprising an effective amount of isolated neutral straight-chain or branched oligosaccharides of a base unit of formula I;

2. The method according to claim 1, wherein the infection is Listeriosis.

3. The method according to claim 1, wherein the oligosaccharides are administered in an amount of at least 1 mg per kg of body weight and per day to a human or an animal.

4. The method according to claim 1, wherein the Listeria bacteria is Listeria monocytogenes.

5. The method according to claim 1, wherein the oligosaccharides are isolated lacto-N-fucopentaose or isolated lacto-N-tetraose.

6. The method according to claim 1, wherein the oligosaccharides are isolated lacto-N-fucopentaose I and said isolated lacto-N-fucopentaose I is immobilized on or absorbed on a carrier.